The technological process of production of biosimilars determines the degree of biosimilarity to the original biological drug. In particular, the focus is on the similarity of immunogenic responses. The primary endpoint of our retrospective study was to find the differences in SARS-CoV-2 antibody amount between patients treated with original adalimumab and biosimilar adalimumab MSB11022 (Idacio) and the differences in the SARS-CoV-2 antibody amount between patients treated with and without biological treatment. We collected the gender, autoimmune disease type, age, and treatment data of the patients in the outpatient clinic MEDICAL PLUS, s.r.o., Uherske Hradiste. These patients suffer from autoimmune rheumatic diseases. All patients received the mRNA vaccine (Pfizer/BioNTech - BNT162b2), with a 21-day (interquartile range, 21-24) gap between the two vaccinations. Patients receiving adalimumab were able to develop cellular immune responses after the second vaccination dose, as well as the individuals without adalimumab. In the period of 6-23 weeks after the second vaccination dose (D63 - D182), the SARS-CoV-2 antibody levels did not change significantly in the patients receiving the original adalimumab, while in the patients receiving biosimilar adalimumab a significant decrease was revealed. A statistically significant difference in the SARS-CoV-2 antibody amount between the patients without biological treatment (median: 504.3 U/mL) and with biological treatment (Original and Biosimilar - median: 47.2 and 28.2 U/mL, respectively) was confirmed on day 182. According to our observation, the effect of the treatment type on the increase/decrease of antibodies over time is dominant, while the impact of other variables (gender, methotrexate treatment, autoimmune disease type, and age) was confirmed as insignificant or minor.

Masaryk University Department of Pharmaceutical Technology Faculty of Pharmacy Brno Czech Republic

Medical Plus s r o Uherske Hradiste Czech Republic

Zobrazit více v PubMed

Alten R., Markland C., Boyce M., Kawakami K., Muniz R., Genovese M.C. Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis. Int. J. Rheumatic Dis. [online]. 2020;23:1514–1525. doi: 10.1111/1756-185X.13951. PubMed DOI PMC

Askling H.H., Rombo L., van Vollenhoven R., Hallén I., Thörner Å., Nordin M., Herzog C., Kantele A. Hepatitis a vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-Centre study. Travel Med. Infect. Dis. [online] 2014;12:134–142. doi: 10.1016/j.tmaid.2014.01.005. PubMed DOI

Assessment Report: Hyrimoz (Procedure No. EMEA/H/C/004320/0000) 2018. https://www.ema.europa.eu/en/documents/assessment-report/hyrimoz-epar-public-assessment-report_en.pdf

Chanchlani N., Lin S., Chee D., Hamilton B., Nice R., Arkir Z., Bewshea C., Cipriano B., Derikx L.A.A.P., Dunlop A., et al. Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients. J. Crohns Colitis. 2022;16:389–397. doi: 10.1093/ecco-jcc/jjab153. PubMed DOI PMC

Chen R.E., Gorman M.J., Zhu D.Y., Carreño J.M., Yuan D., VanBlargan L.A., Burdess S., Lauffenburger D.A., Kim W., Turner J.S., et al. Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors. Med. [online] 2021;2:1327–1341.e4. doi: 10.1016/j.medj.2021.11.004. PubMed DOI PMC

Cohen S., Genovese M.C., Choy E., Perez-Ruiz F., Matsumoto A., Pavelka K., Pablos J.L., Rizzo W., Hrycaj P., Zhang N., et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann. Rheum. Dis. 2017;76:1679–1687. doi: 10.1136/annrheumdis-2016-210459. PubMed DOI PMC

Cohen S.B., Alonso-Ruiz A., Klimiuk P.A., Lee E.C., Peter N., Sonderegger I., Assudani D. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann. Rheum. Dis. 2018;77:914–921. doi: 10.1136/annrheumdis-2017-212245. PubMed DOI PMC

Curtis J.R., Johnson S.R., Anthony D.D., Arasaratnam R.J., Baden L.R., Bass A.R., Calabrese C., Gravallese E.M., Harpaz R., Sadun R.E., et al. American college of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 1. Arthritis Rheumatol. [online] 2021;73:1093–1107. doi: 10.1002/art.41734. PubMed DOI PMC

Dörner T., Strand V., Cornes P., Gonçalves J., Gulácsi L., Kay J., Kvien T.K., Smolen J., Tanaka Y., Burmester G.R. The changing landscape of biosimilars in rheumatology. Ann. Rheum. Dis. 2016;75:974–982. doi: 10.1136/annrheumdis-2016-209166. PubMed DOI PMC

Edwards C.J., Monnet J., Ullmann M., Vlachos P., Chyrok V., Ghori V. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis. Clin. Rheumatol. [online] 2019;38:3381–3390. doi: 10.1007/s10067-019-04679-y. PubMed DOI

Elecsys® Anti-SARS-CoV-2 S . 2020. Package Insert 2020–09, V1.0, Material Numbers 09289267190 and 09289275190.

European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf.

Fleischmann R.M., Alten R., Pileckyte M., Lobello K., Hua S.Y., Cronenberger C., Alvarez D., Bock A.E., Sewell K.L. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira(R)) in the treatment of active rheumatoid arthritis. Arthritis Res. Ther. 2018;20:178. doi: 10.1186/s13075-018-1676-y. PubMed DOI PMC

Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.

Frey S., Chiang T.P., Connolly C.M., Teles M., Alejo J.L., Boyarsky B.J., Christopher-Stine L., Werbel W.A., Massie A.B., Segev D.L., Paik J.J. Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease. Lancet Rheumatol. [online] 2022;4:e241–e243. doi: 10.1016/S2665-9913(21)00417-3. PubMed DOI PMC

Furer V., Rondaan C., Agmon-Levin N., van Assen S., Bijl M., Kapetanovic M.C., de Thurna A., Mueller-Ladner U., Paran D., Schreiber K., et al. Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. RMD Open. 2021;7 doi: 10.1136/rmdopen-2021-001594. PubMed DOI PMC

Gianfrancesco M., Hyrich K.L., Al-Adely S., Carmona L., Danila M.I., Gossec L., Izadi Z., Jacobsohn L., Katz P., Lawson-Tovey S., et al. Characteristics associated with hospitalization for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis. 2020;79:859–866. doi: 10.1136/annrheumdis-2020-217871. PubMed DOI PMC

Haberman R.H., Herati R.S., Simon D., Samanovic M., Blank R.B., Tuen M., Koralov S.B., Atreya R., Tascilar K., Allen J.R., et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann. Rheum. Dis. [online] 2021;80:1339–1344. doi: 10.1136/annrheumdis-2021-220597. PubMed DOI PMC

Hirsch B.R., Lyman G.H. Biosimilars: a cure to the U.S. health care cost conundrum? Blood Rev. 2014;28:263–268. doi: 10.1016/j.blre.2014.08.003. PubMed DOI

Hyland E., Mant T., Vlachos P., Attkins N., Ullman M., Roy S., Wagner V. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira((R)) in healthy subjects. Br. J. Clin. Pharmacol. 2016;82:983–993. doi: 10.1111/bcp.13039. PubMed DOI PMC

Jalkanen P., Kolehmainen P., Häkkinen H.K., Huttunen M., Tähtinen P.A., Lundberg R., Maljanen S., Reinholm A., Tauriainen S., Pakkanen S.H., et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat. Commun. [online] 2021;12:3991. doi: 10.1038/s41467-021-24285-. PubMed DOI PMC

Jani R.H., Gupta R., Bhatia G., Rathi G., Ashok Kumar P., Sharma R., Kumar U., Gauri L.A., Jadhav P., Bartakke G., et al. A prospective, randomized, double-blind, multicentre, parallel- group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia, ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int. J. Rheum. Dis. 2016;19:1157–1168. doi: 10.1111/1756-185X.12711. PubMed DOI PMC

Kaur P., Chow V., Zhang N., Moxness M., Kaliyaperumal A., Markus R. A randomised, single-blind, single-dose, three-arm, parallel group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann. Rheum. Dis. 2017;76:526–533. doi: 10.1136/annrheumdis-2015-208914. PubMed DOI PMC

Lukaszuk K., Woclawek-Potocka I., Jakiel G., Malinowska P., Wdowiak A., Rozanska K., Rabalski L. Humoral response to SARS-CoV-2 vaccine of a patient receiving methotrexate treatment and implications for the need of monitoring. Vaccines [online]. 2021;9:1151. doi: 10.3390/vaccines9101151. PubMed DOI PMC

Markus R., McBride H.J., Ramchandani M., Chow V., Liu J., Mytych D., Fanjiang G., et al. A review of the totality of evidence supporting the development of the first adalimumab biosimilar ABP 501. Adv. Therapy [online] 2019;36:1833–1850. doi: 10.1007/s12325-019-00979-6. PubMed DOI PMC

Michiels Y., Houhou-Fidouh N., Collin G., Berger J., Kohli E. Impact of low-dose methotrexate–adalimumab combination therapy on the antibody response induced by the mRNA-1273 SARS-CoV-2 vaccine: case of an elderly patient with rheumatoid arthritis. Vaccines [online] 2021;9:883. doi: 10.3390/vaccines9080883. PubMed DOI PMC

Millán-Martín S., Jakes C., Carillo S., Bones J. Multi-attribute method (MAM) to assess analytical comparability of adalimumab biosimilars. Online. J. Pharm. Biomed. Anal. 2023:234. doi: 10.1016/j.jpba.2023.115543. ISSN 07317085. PubMed DOI

Muench P., Jochum S., Wenderoth V., Ofenloch-Haehnle B., Hombach M., Strobl M., Sadlowski H., Sachse C., Torriani G., Eckerle I., Riedel A. Development and validation of the elecsys anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2. J. Clin. Microbiol. 2020;58 doi: 10.1128/JCM.01694-20. e01694–20. PubMed DOI PMC

Pellini R., Venuti A., Pimpinelli F., Abril E., Blandino G., Campo F., Conti L., De Virgilio A., De Marco F., Di Domenico E.G., et al. Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClin. Med. [online] 2021;36 doi: 10.1016/j.eclinm.2021.100928. PubMed DOI PMC

Puri A., Niewiarowski A., Arai Y., Nomura H., Baird M., Dalrymple I., Warrington S., Boyce M. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects. British J. Clin. Pharmacol. [online] 2017;83:1405–1415. doi: 10.1111/bcp.13245. PubMed DOI PMC

R Core Team . R Foundation for Statistical Computing; Vienna, Austria: 2021. R: A Language and Environment for Statistical Computing. URL https://www.R-project.org/

Salinas F.G., De Rycke L., Barendregt B., Paramarta J.E., Hreggvidsdottir H., Cantaert T., van der Burg M., Tak P.P., Baeten D. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann. Rheum. Dis. [online] 2013;72:1037–1043. doi: 10.1136/annrheumdis-2011-201270. PubMed DOI

Schreiber S., Yamamoto K., Muniz R., Iwura T. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab. Pharmacol. Res. Perspect. 2020;8 doi: 10.1002/prp2.604. PubMed DOI PMC

Schreiber K., Graversgaard C., Petersen R., Jakobsen H., Bojesen A.B., Krogh N.S., Glintborg B., Hetland M.L., Hendricks O., et al. Reduced humoral response of SARS-CoV-2 antibodies following vaccination in patients with inflammatory rheumatic diseases—an interim report from a Danish prospective Cohort Study. Vaccines [online] 2022;10:35. doi: 10.3390/vaccines10010035. PubMed DOI PMC

Shin D., Lee Y., Kim H., Körnicke T., Fuhr R. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. J. Clin. Pharm. Ther. 2017;42:672–678. doi: 10.1111/jcpt.12583. PubMed DOI

Siemieniuk R.A.C., Bartoszko J.J., Zeraatkar D. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ [online] 2020;30 doi: 10.1136/bmj.m2980. PubMed DOI PMC

Simon D., Tascilar K., Fagni F., Krönke G., Kleyer A., Meder C., Atreya R., Leppkes M., Kremer A.E., Ramming A., et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann. Rheumatic Dis. [online]. 2021;80:1312–1316. doi: 10.1136/annrheumdis-2021-220461. PubMed DOI PMC

Smetanova J., Strizova Z., Sediva A., Milota T., Horvath R. Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab. Lancet Rheumatol. 2022;4:e163–e166. doi: 10.1016/S2665-9913(21)00393-3. PubMed DOI PMC

Smolen J.S., Landewé R., Breedveld F.C., Buch M., Burmester G., Dougados M., Emery P., Gaujoux-Viala C., Gossec L., Nam J., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 2014;73:492–509. doi: 10.1136/annrheumdis-2013-204573. PubMed DOI PMC

Soleimanpour S., Yaghoubi A. COVID-19 vaccine: where are we now and where should we go? Exp. Rev. Vaccines [online] 2021;20:23–44. doi: 10.1080/14760584.2021.1875824. PubMed DOI PMC

Spiera R., Jinich S., Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases. Ann. Rheum. Dis. 2021;80:1357–1359. doi: 10.1136/annrheumdis-2021-220604. PubMed DOI

Strand V., Gonçalves J., Hickling T.P., Jones H.E., Marshall L., Isaacs J.D. Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory documents. BioDrugs [online]. 2020;34:27–37. doi: 10.1007/s40259-019-00394-x. PubMed DOI PMC

Subesinghe S., Bechman K., Rutherford A.I., Goldblatt D., Galloway J.B. A Systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis. J. Rheumatol. [online] 2018;45:733–744. doi: 10.3899/jrheum.170710. PubMed DOI

Vollenberg R., Tepasse P.R., Kühn J.E., Hennies M., Strauss M., Rennebaum F., Schomacher T., Boeckel G., Lorentzen E., Bokemeyer A., Nowacki T.M. Humoral immune response in IBD patients three and six months after vaccination with the SARS-CoV-2 mRNA vaccines mRNA-1273 and BNT162b2. Biomedicines [online] 2022;10:171. doi: 10.3390/biomedicines10010171. PubMed DOI PMC

Weinblatt M.E., Baranauskaite A., Niebrzydowski J., Dokoupilova E., Zielinska A., Jaworski J., Racewicz A., Pileckyte M., Jedrychowicz-Rosiak K., Cheosong S.Y. Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. Arthritis Rheum. 2018;70:40–48. doi: 10.1002/art.40336. PubMed DOI PMC

Weise M., Bielsky M-Ch., De Smet K., Ehmann F., Ekman N., Giezen T.J., Gravanis I., Heim H.-K., Heinonen E., Ho K., et al. Biosimilars: what clinicians should know. Blood [online] 2012;120:5111–5117. doi: 10.1182/blood-2012-04-425744. PubMed DOI

Wheeler S.E., Shurin G.V., Yost M., Anderson A., Pinto L., Wells A., Shurin M.R., Martinez M.A., et al. Differential antibody response to mRNA COVID-19 vaccines in healthy subjects. Microbiol. Spectrum [online] 2021;9 doi: 10.1128/Spectrum.00341-21. e00341–21. PubMed DOI PMC

Wiland P., Jeka S., Dokoupilová E., Brandt-Jürgens J., Miranda Limón J.M., Canralejo Moreira M., Cabello R.V., Jauch-Lembach J., Thakur A., Haliduola H., et al. Switching to biosimilar SDZ-ADL in patients with moderate-to-severe active rheumatoid arthritis: 48-week efficacy, safety and immunogenicity results from the phase III, randomized, double-blind ADMYRA study. BioDrugs [online] 2020;34:809–823. doi: 10.1007/s40259-020-00447-6. PubMed DOI PMC

Wynne C., Altendorfer M., Sonderegger I., Gheyle L., Ellis-Pegler R., Buschke S., Lang B., Assundani D., Athalye S., Czeloth N., et al. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE(R)-PK) in healthy subjects. Expert Opin. Investig. Drugs. 2016;25:1361–1370. doi: 10.1080/13543784.2016.1255724. PubMed DOI

Zhao S., Chadwick L., Mysler E., Moots R.J. Review of biosimilar trials and data on adalimumab in rheumatoid arthritis. Curr. Rheumatol. Rep. [online] 2018;20:57. doi: 10.1007/s11926-018-0769-6. PubMed DOI PMC